Cambridge is to host an historic alliance between scientists at AstraZeneca and investigators at Cancer Research UK designed to push the boundaries of cancer discovery and generate new drugs.
Pfizer Venture Investments has pumped cash into Cambridge biotechnology company MISSION Therapeutics in a $32 million Series B round of equity financing.
A transatlantic alliance between Horizon Discovery in the UK and Adarza in the US promises further progress for the development of personalised medicines.
Cambridge stem cell pioneer DefiniGEN is in China this week showcasing technology that arguably gives the UK a world lead in countering liver and pancreatic cancer.
Endomagnetics, the Cambridge UK cancer healthcare company, has raised an extra £2m to support a pivotal US clinical trial and the launch of a new cancer marker product in 2015.
Cambridge UK medical technology business Horizon Discovery Group has landed another major deal with a top 10 pharmaceutical company to profile a lead cancer asset.
A delegation of senior directors from state-owned Shanghai Hospital Development Centre (SHDC) have been in Cambridge to learn best practice in healthcare and medical technology from leading medics – knowledge that will underpin future strategy in China.
Labour Parliamentary candidate Daniel Zeichner cut the ribbon on Owlstone's new manufacturing facility on the Cambridge Science Park.
Two Cambridge University scientists have launched a crowdfunding campaign to help develop their vision to build lung tissue in the lab. They believe the technology using stem cells could prove significant in combating lung cancer.
Cambridge cancer drug pioneer Sareum has earned a crucial first patent from the European Patent Office for inventions associated with its TYK2 kinase inhibitor programme – technology that could improve treatment of a range of auto immune diseases.
A Cambridge UK medical technology startup which matches safe drugs to rare diseases is working on a potential cure for a six-year-old American boy who is the first patient ever to be diagnosed with NGLY-1 deficiency and loss of function.
A hundred years after his death on the Western Front a British soldier is still fighting – this time to save the lives of children dying from dysentry in developing countries.
For an entity awaiting a heart transplant – moving the heart of its corporate and R & D business to the Cambridge medical technology cluster – AstraZeneca looks in remarkably rude health.
BioSilta Ltd, a developer of advanced, reagent-based microbial growth systems, has completed the set-up of operational and commercial headquarters in St Ives.
F-star, the Cambridge UK oncology-focused biopharma company, has launched an independent spin-out business – F-star Beta – which has been granted exclusive licences to a range of oncology assets.
MedImmune, AstraZeneca’s Cambridge UK-based biologics R & D arm, has agreed to buy Definiens – a German company that has pioneered a world-leading imaging and data analysis technology – in a deal worth an initial $150 million plus certain milestones.
- Tech spy inside the body will diagnose cancer faster
- Wall Street giant could take F-star for up to $475m
- TGAC nurtures the genomics generation
- Cambridge tech at heart of £53m dementia research platform
- New CEO as Cambridge Epigenetix raises $5.5m
- Babraham signals greater engagement with industry
- AZ lines up second Cambridge blockbuster drug
- Global injector drug deal for Consort Medical
- Cambridge drug hope for lethal child epilepsy
- Freewheeling Bicycle Therapeutics raises $32 million
- Cambridge-Sydney alliance seeks drugs to fight killer bugs
- Horizon wins $450k deal with top 10 Pharma business
- BioSilta and Sigma-Aldrich in cell culture alliance
- Sphere Medical praised for patient care advance
- Tristel stock tipped to go higher
- DIY doctor technology hits home
Page 1 of 66